Tithi Biswas

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Stereotactic radiosurgery for glioblastoma: retrospective analysis
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiat Oncol 4:11. 2009
  2. ncbi Low-dose radiosurgery for benign intracranial lesions
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center Rochester, New York 14642-8647, USA
    Am J Clin Oncol 26:325-31. 2003
  3. ncbi Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Int J Radiat Oncol Biol Phys 77:79-85. 2010

Detail Information

Publications3

  1. ncbi Stereotactic radiosurgery for glioblastoma: retrospective analysis
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Radiat Oncol 4:11. 2009
    ..This retrospective study was done to better understand the conditions for which stereotactic radiosurgery (SRS) for glioblastoma may be efficacious...
  2. ncbi Low-dose radiosurgery for benign intracranial lesions
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center Rochester, New York 14642-8647, USA
    Am J Clin Oncol 26:325-31. 2003
    ..If lower, more homogeneous radiation doses produce responses as durable as higher doses, then toxicity might be further reduced...
  3. ncbi Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era
    Tithi Biswas
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Int J Radiat Oncol Biol Phys 77:79-85. 2010
    ..We evaluated the role of involved field radiation therapy (IFRT) post-ASCT for patients initially induced with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or, more recently, rituximab-CHOP (R-CHOP)...